{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T20:20:28Z","timestamp":1791058828126,"version":"4.1.0"},"reference-count":25,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2007,9,17]],"date-time":"2007-09-17T00:00:00Z","timestamp":1189987200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Nephrology"],"published-print":{"date-parts":[[2008,6]]},"abstract":"<jats:title>SUMMARY:<\/jats:title><jats:p><jats:bold>Background:\u2003<\/jats:bold>The ideal treatment of lupus nephritis has yet to be defined. Both cyclophosphamide and mycophenolate mofetil have been used with encouraging results, but adverse events are frequently seen. There are no data on the use of enteric\u2010coated mycophenolate sodium.<\/jats:p><jats:p><jats:bold>Methods:\u2003<\/jats:bold>We retrospectively reviewed 12 patients with active forms of lupus nephritis (1 class III, 7 class IV and 4 class V) treated with enteric\u2010coated mycophenolate sodium combined with corticosteroids.<\/jats:p><jats:p><jats:bold>Results:\u2003<\/jats:bold>The mean age of the patients was 32.3\u2003\u00b1\u200311.2\u2003years and the average length of follow up was 25.9\u2003\u00b1\u20038.9\u2003months. The mean serum creatinine clearance was 93\u2003\u00b1\u200330.1\u2003mL\/min per 1.73\u2003m<jats:sup>2<\/jats:sup>and the mean proteinuria level was 4.5\u2003\u00b1\u20033.6\u2003g\/day. All had features that warranted aggressive treatment. Mycophenolate sodium was given for 12.9\u2003\u00b1\u20039.7\u2003months with an averaged starting dose of 1350\u2003\u00b1\u2003163\u2003mg\/day. Six patients attained complete remission and six attained partial remission with treatment. The mean interval to attain first remission (complete or partial) was 8.3\u2003\u00b1\u20035.7\u2003weeks. At last follow up, all patients were in complete or partial remission. Apart from herpes zoster that developed in one patient, no other significant side\u2010effects were encountered.<\/jats:p><jats:p><jats:bold>Conclusion:\u2003<\/jats:bold>Enteric\u2010coated mycophenolate sodium was effective and well\u2010tolerated in the treatment of active lupus nephritis.<\/jats:p>","DOI":"10.1111\/j.1440-1797.2007.00862.x","type":"journal-article","created":{"date-parts":[[2007,9,19]],"date-time":"2007-09-19T04:30:14Z","timestamp":1190176214000},"page":"331-336","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy of enteric\u2010coated mycophenolate sodium in patients with active lupus nephritis"],"prefix":"10.1111","volume":"13","author":[{"given":"SIU\u2010KA","family":"MAK","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KIN\u2010YEE","family":"LO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MAN\u2010WAI","family":"LO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SHUK\u2010FAN","family":"CHAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GENSY MW","family":"TONG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PING\u2010NAM","family":"WONG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ANDREW KM","family":"WONG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,9,17]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"crossref","unstructured":"ChanTM TseKC TangCSO MokMY LiFK for the Hong Kong Nephrology Study Group.Long\u2010term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis.J. Am. Soc. Nephrol.2005;16:1076\u201384.","DOI":"10.1681\/ASN.2004080686"},{"key":"e_1_2_5_3_2","doi-asserted-by":"crossref","unstructured":"GinzlerEM DooleyMA AranowCet\u2003al.Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis.N. Engl. J. Med.2005;353:2219\u201328.","DOI":"10.1056\/NEJMoa043731"},{"key":"e_1_2_5_4_2","unstructured":"HuW LiuZ ChenHet\u2003al.Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis.Chin. Med. J.2002;115:705\u20139."},{"key":"e_1_2_5_5_2","doi-asserted-by":"crossref","unstructured":"OngLM HooiLS LimTOet\u2003al.Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis.Nephrology2005;10:504\u201310.","DOI":"10.1111\/j.1440-1797.2005.00444.x"},{"key":"e_1_2_5_6_2","doi-asserted-by":"crossref","unstructured":"SpetieDN TangY RovinBHet\u2003al.Mycophenolate therapy of SLE membranous nephropathy.Kidney. Int.2004;66:2411\u201315.","DOI":"10.1111\/j.1523-1755.2004.66030.x"},{"key":"e_1_2_5_7_2","doi-asserted-by":"crossref","unstructured":"MooreRA DerryS.Systematic review and meta\u2010analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis.Arthritis. Res. Ther.2006;8:R182.","DOI":"10.1186\/ar2093"},{"key":"e_1_2_5_8_2","doi-asserted-by":"crossref","unstructured":"AllisonAC EuguiEM.Mycophenolate mofetil and its mechanisms of action.Immunopharmacology2000;47:85\u2013118.","DOI":"10.1016\/S0162-3109(00)00188-0"},{"key":"e_1_2_5_9_2","doi-asserted-by":"crossref","unstructured":"EuguiEM AlmquistSJ MullerCD AllisonAC.Lymphocyte\u2010selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: Role of deoxyguanosine nucleotide depletion.Scand. J. Immunol.1991;33:161\u201373.","DOI":"10.1111\/j.1365-3083.1991.tb03746.x"},{"key":"e_1_2_5_10_2","doi-asserted-by":"crossref","unstructured":"SalvadoriM HolzerH De MattosAet\u2003al. The ERL B301 Study Group.Enteric\u2010coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil inde novorenal transplant patients.Am. J. Transplant.2004;4:231\u20136.","DOI":"10.1046\/j.1600-6143.2003.00337.x"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2005.01.063"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1600-6143.2003.00321.x"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2004.12.048"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000209411.66790.b3"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780251101"},{"key":"e_1_2_5_16_2","volume-title":"Renal Disease: Classification and Atlas of Glomerular Diseases","author":"Churg J","year":"1995"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1984.75"},{"key":"e_1_2_5_18_2","first-page":"447","article-title":"The BILAG index: A reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus","volume":"86","author":"Hay EM","year":"1993","journal-title":"Q. J. Med."},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(00)70262-9"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)92292-N"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5001777"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199834060-00002"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/41.7.1011"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5001722"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200010193431604"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1191\/096120398678919723"}],"container-title":["Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1440-1797.2007.00862.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1440-1797.2007.00862.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T02:55:59Z","timestamp":1737428159000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1440-1797.2007.00862.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9,17]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["10.1111\/j.1440-1797.2007.00862.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1440-1797.2007.00862.x","archive":["Portico"],"relation":{},"ISSN":["1320-5358","1440-1797"],"issn-type":[{"value":"1320-5358","type":"print"},{"value":"1440-1797","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,9,17]]},"assertion":[{"value":"2007-09-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}